SRNMF (Sirnaomics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is Sirnaomics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Sirnaomics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

SRNMF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Sirnaomics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirnaomics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirnaomics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Sirnaomics's Margin of Safety % (DCF Earnings Based) falls into.


Sirnaomics Business Description

Other Exchanges 02257:Hong Kong
Address No.218 Xinghu Street, Unit 415, A4 Building, Suzhou Industrial Park, Suzhou, CHN
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group's operations and non-current assets are located at the United States of America and the mainland of the People's Republic of China. All of the company's revenue is derived from the mainland of the People's Republic of China (the PRC). The pipeline includes: STP705, STP707, STP355, STP369, STP705, STP122G, STP125G, and STP144G.